SVB provided financial services to nearly half the venture-backed technology and life sciences startups in 2022.March 10, 2023Check out STAT+Sponsored By Adobe STAT+ | SVB, biotech's bank of choice, just failed. It could have ripple effects SVB provided financial services to nearly half the venture-backed technology and life sciences startups in 2022. By Adam Feuerstein and Damian Garde and Allison DeAngelis STAT+ | Several years later, AstraZeneca says its drug extends life for some early-stage lung cancers Several years after osimertinib was shown to deter recurrence of lung cancers, it wasn't known until now if it extended survival as well. By Angus Chen STAT+ | Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn't affect prices Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show those factors don't affect prices. By Joanne Silberner Dom Smith/STAT Opinion: Ranked to fail: Does gatekeeping affect diversity in The Match? The National Residency Matching Program needs to share demographic data on students who do not match into residency programs. By Onyekachi T. Otugo and Al'ai Alvarez and Adaira I. Landry Opinion: Clearing the patent thicket: A pathway to faster generic drug approvals The widespread use of patent thickets to delay generic competition results from a mistake by the FDA in interpreting the Hatch-Waxman Act. By Alfred Engelberg More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments